Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2014 Filed May 6, 2014 20:30 UTC |
Pace Megan ESVP, Corp. Communications
|
SaleCommon Stock | 100 | $69.42 | $6,942.00 |
DisclosureSEC source: 0001209191-14-031519 · doc4.xml · nonDerivative · entry 3 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,350 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 02, 2014 Filed May 6, 2014 20:30 UTC |
Pace Megan ESVP, Corp. Communications
|
SaleCommon Stock | 400 | $67.94 | $27,176.00 |
DisclosureSEC source: 0001209191-14-031519 · doc4.xml · nonDerivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $67.94 (range $67.73 to $68.24). Read SEC document |
| May 02, 2014 Filed May 6, 2014 20:30 UTC |
Pace Megan ESVP, Corp. Communications
|
SaleCommon Stock | 500 | $67.01 | $33,505.00 |
DisclosureSEC source: 0001209191-14-031519 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,850 F1 · kind: Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $67.01 (range $66.49 to $67.40). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option (righty to buy) · Derivative | 5,750 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · derivative · entry 10 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 5,750 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · derivative · entry 9 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 700 | $63.27 | $44,289.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $63.27 (range $63.03 to $63.65). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 1,800 | $62.38 | $112,284.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,450 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $62.38 (range $62.00 to $62.84). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 2,900 | $61.53 | $178,437.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,250 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $61.53 (range $61.05 to $61.97). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 2,100 | $60.57 | $127,197.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,150 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $60.57 (range $60.06 to $60.94). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 5,750 | $32.16 | $184,920.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 1,750 | $28.84 | $50,470.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2014 Filed Apr 11, 2014 20:16 UTC |
ULLIAN ELAINEDirector
|
Exercise / conversionStock Option(right to buy) · Derivative | 2,500 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-14-027157 · doc4.xml · derivative · entry 3 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 2,500 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| April 09, 2014 Filed Apr 11, 2014 20:16 UTC |
ULLIAN ELAINEDirector
|
SaleCommon Stock | 2,500 | $70.00 | $175,000.00 |
DisclosureSEC source: 0001209191-14-027157 · doc4.xml · nonDerivative · entry 2 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,265 F1 · kind: Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1. Read SEC document |
| April 09, 2014 Filed Apr 11, 2014 20:16 UTC |
ULLIAN ELAINEDirector
|
Exercise / conversionCommon Stock | 2,500 | $34.32 | $85,800.00 |
DisclosureSEC source: 0001209191-14-027157 · doc4.xml · nonDerivative · entry 1 ULLIAN ELAINE · CIK 0001190290 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 500 | $76.57 | $38,285.00 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $76.57 (range $76.22 to $76.74). Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 3,000 | $75.25 | $225,750.00 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $75.25 (range $75.00 to $75.85). Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 2,750 | $74.47 | $204,792.50 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $74.47 (range $73.99 to $74.96). Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 2,450 | $73.53 | $180,148.50 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,460 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $73.53 (range $72.99 to $73.98). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 7,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 1,220 | $78.78 | $96,111.60 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $78.78 (range $78.50 to $79.36). Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 6,280 | $78.19 | $491,033.20 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,970 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $78.19 (range $77.50 to $78.49). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 7,500 | $28.84 | $216,300.00 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 21:30 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 3,200 | $84.13 | $269,216.00 |
DisclosureSEC source: 0001209191-14-013508 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $84.13 (range $84.02 to $84.35). Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 21:30 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 3,800 | $83.65 | $317,870.00 |
DisclosureSEC source: 0001209191-14-013508 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,110 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $83.65 (range $83.16 to $83.99). Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 21:30 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 1,300 | $82.51 | $107,263.00 |
DisclosureSEC source: 0001209191-14-013508 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $82.51 (range $82.00 to $82.99). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 7,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 633 | $83.05 | $52,570.65 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $83.05 (range $82.96 to $83.18). Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
SaleCommon Stock | 6,867 | $82.55 | $566,870.85 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,383 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $82.55 (range $81.95 to $82.92). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
Exercise / conversionCommon Stock | 7,500 | $28.84 | $216,300.00 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2014 Filed Feb 11, 2014 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 35,944 | $80.00 | $2,875,520.00 |
DisclosureSEC source: 0001209191-14-009094 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,481 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:02 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008348 · doc4.xml · derivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:02 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantCommon Stock | 20,700 | $0.01 | $207.00 |
DisclosureSEC source: 0001209191-14-008348 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,418 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Connolly ThomasSVP, Human Resources
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 938 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · derivative · entry 7 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 938 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Connolly ThomasSVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 62,750 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · derivative · entry 6 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,750 Underlying: Common Stock · 62,750 shares Expires 2024-02-04 F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Connolly ThomasSVP, Human Resources
|
SaleCommon Stock | 738 | $77.83 | $57,438.54 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,647 F2 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $77.83 (range $77.47 to $78.13). Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Connolly ThomasSVP, Human Resources
|
SaleCommon Stock | 200 | $76.82 | $15,364.00 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,385 F2 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $76.82 (range $76.49 to $77.14). F4 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Connolly ThomasSVP, Human Resources
|
Exercise / conversionCommon Stock | 938 | $45.11 | $42,313.18 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Connolly ThomasSVP, Human Resources
|
GrantCommon Stock | 11,875 | $0.01 | $118.75 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,647 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Horton Kenneth LEVP & Chief Legal Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 51,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008354 · doc4.xml · derivative · entry 3 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC |
Horton Kenneth LEVP & Chief Legal Officer
|
GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-14-008354 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,874 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:05 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantEmployee Stock Option (right to buy) · Derivative | 213,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008355 · doc4.xml · derivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:05 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 64,500 | $0.01 | $645.00 |
DisclosureSEC source: 0001209191-14-008355 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,425 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
GrantEmployee Stock Option (right to buy) · Derivative | 51,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008356 · doc4.xml · derivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC |
MUELLER PETEREVP, Global R&D, CSO
|
GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-14-008356 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC |
Pace Megan ESVP, Corp. Communications
|
GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008357 · doc4.xml · derivative · entry 2 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:06 UTC |
Pace Megan ESVP, Corp. Communications
|
GrantCommon Stock | 14,250 | $0.01 | $142.50 |
DisclosureSEC source: 0001209191-14-008357 · doc4.xml · nonDerivative · entry 1 Pace Megan E · CIK 0001554979 · SVP, Corp. Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,350 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:07 UTC |
Sachdev AmitSVP, Global Gov. Strategy
|
GrantEmployee Stock Option (right to buy) · Derivative | 41,250 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008358 · doc4.xml · derivative · entry 3 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 41,250 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/5/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:07 UTC |
Sachdev AmitSVP, Global Gov. Strategy
|
GrantCommon Stock | 11,875 | $0.01 | $118.75 |
DisclosureSEC source: 0001209191-14-008358 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · SVP, Global Gov. Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,436 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:07 UTC |
Silva Paul MSVP & Corp Controller
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,625 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008359 · doc4.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 20,625 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:07 UTC |
Silva Paul MSVP & Corp Controller
|
GrantCommon Stock | 6,875 | $0.01 | $68.75 |
DisclosureSEC source: 0001209191-14-008359 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,625 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.